神経膠腫治療市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポート対象範囲疾患別（星細胞腫、乏突起星細胞腫、乏突起膠腫）、治療タイプ別（手術、化学療法、放射線療法、その他）、グレード別（低グレード、高グレード）、エンドユーザー別（病院＆クリニック、外来手術センター）、地域別

Glioma Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography

世界の神経膠腫治療市場は、2022年の41億3,960万米ドルから2030年には82億9,250万米ドルに達すると予測される。2022年から2030年までの年平均成長率は9.1%と予測されている。市場の成長は、膠芽腫、退形成性... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2023年9月18日	US$4,550 シングルユーザライセンスライセンス・価格情報注文方法はこちら	182	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

世界の神経膠腫治療市場は、2022年の41億3,960万米ドルから2030年には82億9,250万米ドルに達すると予測される。2022年から2030年までの年平均成長率は9.1%と予測されている。

市場の成長は、膠芽腫、退形成性星細胞腫、乏突起膠腫などの侵攻性脳腫瘍を含む高悪性度神経膠腫の有病率の増加である。しかし、高い治療費が市場の成長をある程度妨げている。

神経膠腫治療市場の市場機会

ブラジル、インド、中国、ロシア、南アフリカは、世界で最も急速に経済成長している国のひとつである。これらの国々やその他の発展途上国の医療部門は、今後数年間で急速に拡大すると予測されています。期待される成長の背景には、顧客需要の変化、医療サービスに対する意識の高まり、高齢化人口の継続的な増加がある。世界の脳腫瘍治療市場は、医療部門の普及に伴い、今後数年間で大きく成長する可能性が高い。

神経膠腫治療市場の阻害要因

脳腫瘍の治療には高額な費用がかかるため、治療費の高さが患者のストレスや不安の原因となっている。治療費に加えて、患者のケアに関連する予定外の追加費用も負担する必要がある。高額な医療費は、治療計画の中止を余儀なくさせ、健康を危険にさらし、将来のさらなる出費につながる可能性がある。米国国立医学図書館によると、新たにテモゾロミド（TMZ）治療を受けたGBMと診断された場合、商業保険に加入している患者の直接的な医療費は相当なもので、推定累積費用は〜268,031米ドルである。悪性脳腫瘍患者が負担する医療費は、同じ人口統計の非がん対照群が負担する医療費の20倍である。

神経膠腫治療市場セグメント別概要

神経膠腫治療市場は、タイプ別に星細胞腫、乏突起星細胞腫、乏突起膠腫に区分される。2022年には、星細胞腫セグメントが最大の市場シェアを占めている。さらに、このセグメントは2022年から2030年にかけて最も高いCAGRを記録すると予想されている。この疾患の有病率の増加と相まって、この疾患とその治療に対する一般市民の認識を高める活動が活発化していることが、神経膠腫治療市場の成長を促進する主な要因の1つである。さらに、退形成性星細胞腫分野の企業は、研究開発努力の高まりと未開拓の新規市場セグメントから成長機会を得る可能性がある。治療法に基づき、神経膠腫治療市場は手術、化学療法、放射線療法、その他に区分される。2022年には、外科手術分野が市場最大のシェアを占めている。また、手術は腫瘍を完全に除去するため、最も好まれる手法であることから、同分野は2022年から2030年にかけて最も速いCAGRで需要が伸びると予想される。悪性度に基づき、神経膠腫治療市場は低悪性度と高悪性度に区分される。2022年には、高悪性度セグメントが市場最大のシェアを占めている。また、同セグメントは2022年から2030年にかけて最も速い年平均成長率で需要が拡大すると予想されている。より効果的な治療法や療法を開発するために、高悪性度腫瘍をより深く理解するための複数の研究が進行中である。神経膠腫治療市場は、エンドユーザーに基づいて病院・診療所と外来医療センターに区分される。2022年には、病院・診療所セグメントが最大の市場シェアを占めている。さらに、同セグメントは2022年から2030年にかけて最も速いCAGRで需要の伸びが見込まれている。さらに、病院数の増加、先進的な診断プラットフォームの採用、発展途上国における病院へのアクセス性の向上は、予測期間中、病院セグメントの神経膠腫治療市場の成長に有利な機会を提供するであろう。

神経膠腫治療市場地理的概観

世界の神経膠腫治療市場では、北米が最大のシェアを占めているのに対し、アジア太平洋地域は急成長している地域である。北米の市場は、主に脳腫瘍の有病率の増加、神経膠腫治療の技術的進歩、喫煙者の増加によって、予測期間中に成長すると予想される。世界の神経膠腫治療検査市場では、アジア太平洋地域が最も高いCAGRを記録した。同地域の市場は、中国、インド、日本を含む国々で今後数年間に大きく成長すると予想される。アジア太平洋市場は、脳腫瘍治療に対する需要の増加と脳腫瘍の有病率の上昇によって成長すると予想されている。したがって、この地域は神経膠腫治療市場のプレーヤーにとって、予測期間中に成長する大きな可能性を秘めている。

神経膠腫治療市場に関するレポート作成時に参照した一次および二次情報源には、世界銀行データ、国民保健サービス（NHS）、FDA（食品医薬品局）、EMA（欧州医薬品庁）、EPA（環境保護庁）などがあります。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Glioma Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Glioma Treatment Market - Key Industry Dynamics
5.1 Market Drivers
5.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
5.1.2 Increase in Prevalence of High-Grade Glioma
5.2 Key Market Restraints
5.2.1 High Cost of Diagnosis
5.3 Key Market Opportunities
5.3.1 Advancements in Healthcare Sector in Emerging Economies
5.4 Future Trends
5.4.1 Surge in Drug Approvals for Glioma Treatment
5.5 Impact Analysis:
6. Glioma Treatment Market - Global Market Analysis
6.1 Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
7. Global Glioma Treatment Market – Revenue and Forecast to 2030 – by Disease
7.1 Overview
7.2 Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
7.3 Astrocytoma
7.3.1 Overview
7.3.2 Astrocytoma: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Oligoastrocytoma
7.4.1 Overview
7.4.2 Oligoastrocytoma: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Oligodendroglioma
7.5.1 Overview
7.5.2 Oligodendroglioma: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8. Global Glioma Treatment Market – Revenue and Forecast to 2030 – by Treatment Type
8.1 Overview
8.2 Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
8.3 Surgery
8.3.1 Overview
8.3.2 Surgery: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Chemotherapy
8.4.1 Overview
8.4.2 Chemotherapy: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Radiation Therapy
8.5.1 Overview
8.5.2 Radiation Therapy: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Glioma Treatment Market – Revenue and Forecast to 2030 – by Grade
9.1 Overview
9.2 Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
9.3 Low Grade
9.3.1 Overview
9.3.2 Low Grade: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.1 Grade I: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.2 Grade II: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4 High Grade
9.4.1 Overview
9.4.2 High Grade: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4.2.1 Grade III: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4.2.2 Grade IV: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10. Global Glioma Treatment Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Hospital & Clinics
10.3.1 Overview
10.3.2 Hospital & Clinics: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Ambulatory Surgical Centers
10.4.1 Overview
10.4.2 Ambulatory Surgical Centers: Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
11. Glioma Treatment Market - Geographical Analysis
11.1 North America Glioma Treatment Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.2 North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.1.3 North America Glioma Treatment Market, by Disease
11.1.4 North America Glioma Treatment Market, by Treatment Type
11.1.5 North America Glioma Treatment Market, by Grade
11.1.5.1 North America Glioma Treatment Market, by Low Grade
11.1.5.2 North America Glioma Treatment Market, by High Grade
11.1.6 North America Glioma Treatment Market, by End User
11.1.7 North America Glioma Treatment Market, by Country
11.1.7.1 US
11.1.7.1.1 US Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.1.2 US Glioma Treatment Market, by Disease
11.1.7.1.3 US Glioma Treatment Market, by Treatment Type
11.1.7.1.4 US Glioma Treatment Market, by Grade
11.1.7.1.4.1 US Glioma Treatment Market, by Low Grade
11.1.7.1.4.2 US Glioma Treatment Market, by High Grade
11.1.7.1.5 US Glioma Treatment Market, by End User
11.1.7.2 Canada
11.1.7.2.1 Canada Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.2.2 Canada Glioma Treatment Market, by Disease
11.1.7.2.3 Canada Glioma Treatment Market, by Treatment Type
11.1.7.2.4 Canada Glioma Treatment Market, by Grade
11.1.7.2.4.1 Canada Glioma Treatment Market, by Low Grade
11.1.7.2.4.2 Canada Glioma Treatment Market, by High Grade
11.1.7.2.5 Canada Glioma Treatment Market, by End User
11.1.7.3 Mexico
11.1.7.3.1 Mexico Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.3.2 Mexico Glioma Treatment Market, by Disease
11.1.7.3.3 Mexico Glioma Treatment Market, by Treatment Type
11.1.7.3.4 Mexico Glioma Treatment Market, by Grade
11.1.7.3.4.1 Mexico Glioma Treatment Market, by Low Grade
11.1.7.3.4.2 Mexico Glioma Treatment Market, by High Grade
11.1.7.3.5 Mexico Glioma Treatment Market, by End User
11.2 Europe Glioma Treatment Market, Revenue and Forecast to 2030
11.2.1 Overview
11.2.2 Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.3 Europe Glioma Treatment Market, by Disease
11.2.4 Europe Glioma Treatment Market, by Treatment Type
11.2.5 Europe Glioma Treatment Market, by Grade
11.2.5.1 Europe Glioma Treatment Market, by Low Grade
11.2.5.2 Europe Glioma Treatment Market, by High Grade
11.2.6 Europe Glioma Treatment Market, by End User
11.2.7 Europe Glioma Treatment Market, by Country
11.2.7.1 UK
11.2.7.1.1 UK Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.1.2 UK Glioma Treatment Market, by Disease
11.2.7.1.3 UK Glioma Treatment Market, by Treatment Type
11.2.7.1.4 UK Glioma Treatment Market, by Grade
11.2.7.1.4.1 UK Glioma Treatment Market, by Low Grade
11.2.7.1.4.2 UK Glioma Treatment Market, by High Grade
11.2.7.1.5 UK Glioma Treatment Market, by End User
11.2.7.2 Germany
11.2.7.2.1 Germany Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.2.2 Germany Glioma Treatment Market, by Disease
11.2.7.2.3 Germany Glioma Treatment Market, by Treatment Type
11.2.7.2.4 Germany Glioma Treatment Market, by Grade
11.2.7.2.4.1 Germany Glioma Treatment Market, by Low Grade
11.2.7.2.4.2 Germany Glioma Treatment Market, by High Grade
11.2.7.2.5 Germany Glioma Treatment Market, by End User
11.2.7.3 France
11.2.7.3.1 France Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.3.2 France Glioma Treatment Market, by Disease
11.2.7.3.3 France Glioma Treatment Market, by Treatment Type
11.2.7.3.4 France Glioma Treatment Market, by Grade
11.2.7.3.4.1 France Glioma Treatment Market, by Low Grade
11.2.7.3.4.2 France Glioma Treatment Market, by High Grade
11.2.7.3.5 France Glioma Treatment Market, by End User
11.2.7.4 Italy
11.2.7.4.1 Italy Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.4.2 Italy Glioma Treatment Market, by Disease
11.2.7.4.3 Italy Glioma Treatment Market, by Treatment Type
11.2.7.4.4 Italy Glioma Treatment Market, by Grade
11.2.7.4.4.1 Italy Glioma Treatment Market, by Low Grade
11.2.7.4.4.2 Italy Glioma Treatment Market, by High Grade
11.2.7.4.5 Italy Glioma Treatment Market, by End User
11.2.7.5 Spain
11.2.7.5.1 Spain Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.5.2 Spain Glioma Treatment Market, by Disease
11.2.7.5.3 Spain Glioma Treatment Market, by Treatment Type
11.2.7.5.4 Spain Glioma Treatment Market, by Grade
11.2.7.5.4.1 Spain Glioma Treatment Market, by Low Grade
11.2.7.5.4.2 Spain Glioma Treatment Market, by High Grade
11.2.7.5.5 Spain Glioma Treatment Market, by End User
11.2.7.6 Rest of Europe
11.2.7.6.1 Rest of Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.2.7.6.2 Rest of Europe Glioma Treatment Market, by Disease
11.2.7.6.3 Rest of Europe Glioma Treatment Market, by Treatment Type
11.2.7.6.4 Rest of Europe Glioma Treatment Market, by Grade
11.2.7.6.4.1 Rest of Europe Glioma Treatment Market, by Low Grade
11.2.7.6.4.2 Rest of Europe Glioma Treatment Market, by High Grade
11.2.7.6.5 Rest of Europe Glioma Treatment Market, by End User
11.3 Asia Pacific Glioma Treatment Market, Revenue and Forecast to 2030
11.3.1 Overview
11.3.2 Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.3 Asia Pacific Glioma Treatment Market, by Disease
11.3.4 Asia Pacific Glioma Treatment Market, by Treatment Type
11.3.5 Asia Pacific Glioma Treatment Market, by Grade
11.3.5.1 Asia Pacific Glioma Treatment Market, by Low Grade
11.3.5.2 Asia Pacific Glioma Treatment Market, by High Grade
11.3.6 Asia Pacific Glioma Treatment Market, by End User
11.3.7 Asia Pacific Glioma Treatment Market, by Country
11.3.7.1 China
11.3.7.1.1 China Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.1.2 China Glioma Treatment Market, by Disease
11.3.7.1.3 China Glioma Treatment Market, by Treatment Type
11.3.7.1.4 China Glioma Treatment Market, by Grade
11.3.7.1.4.1 China Glioma Treatment Market, by Low Grade
11.3.7.1.4.2 China Glioma Treatment Market, by High Grade
11.3.7.1.5 China Glioma Treatment Market, by End User
11.3.7.2 Japan
11.3.7.2.1 Japan Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.2.2 Japan Glioma Treatment Market, by Disease
11.3.7.2.3 Japan Glioma Treatment Market, by Treatment Type
11.3.7.2.4 Japan Glioma Treatment Market, by Grade
11.3.7.2.4.1 Japan Glioma Treatment Market, by Low Grade
11.3.7.2.4.2 Japan Glioma Treatment Market, by High Grade
11.3.7.2.5 Japan Glioma Treatment Market, by End User
11.3.7.3 India
11.3.7.3.1 India Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.3.2 India Glioma Treatment Market, by Disease
11.3.7.3.3 India Glioma Treatment Market, by Treatment Type
11.3.7.3.4 India Glioma Treatment Market, by Grade
11.3.7.3.4.1 India Glioma Treatment Market, by Low Grade
11.3.7.3.4.2 India Glioma Treatment Market, by High Grade
11.3.7.3.5 India Glioma Treatment Market, by End User
11.3.7.4 South Korea
11.3.7.4.1 South Korea Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.4.2 South Korea Glioma Treatment Market, by Disease
11.3.7.4.3 South Korea Glioma Treatment Market, by Treatment Type
11.3.7.4.4 South Korea Glioma Treatment Market, by Grade
11.3.7.4.4.1 South Korea Glioma Treatment Market, by Low Grade
11.3.7.4.4.2 South Korea Glioma Treatment Market, by High Grade
11.3.7.4.5 South Korea Glioma Treatment Market, by End User
11.3.7.5 Australia
11.3.7.5.1 Australia Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.5.2 Australia Glioma Treatment Market, by Disease
11.3.7.5.3 Australia Glioma Treatment Market, by Treatment Type
11.3.7.5.4 Australia Glioma Treatment Market, by Grade
11.3.7.5.4.1 Australia Glioma Treatment Market, by Low Grade
11.3.7.5.4.2 Australia Glioma Treatment Market, by High Grade
11.3.7.5.5 Australia Glioma Treatment Market, by End User
11.3.7.6 Rest of Asia Pacific
11.3.7.6.1 Rest of Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.3.7.6.2 Rest of Asia Pacific Glioma Treatment Market, by Disease
11.3.7.6.3 Rest of Asia Pacific Glioma Treatment Market, by Treatment Type
11.3.7.6.4 Rest of Asia Pacific Glioma Treatment Market, by Grade
11.3.7.6.4.1 Rest of Asia Pacific Glioma Treatment Market, by Low Grade
11.3.7.6.4.2 Rest of Asia Pacific Glioma Treatment Market, by High Grade
11.3.7.6.5 Rest of Asia Pacific Glioma Treatment Market, by End User
11.4 Middle East & Africa Glioma Treatment Market, Revenue and Forecast to 2030
11.4.1 Overview
11.4.2 Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.4.3 Middle East & Africa Glioma Treatment Market, by Disease
11.4.4 Middle East & Africa Glioma Treatment Market, by Treatment Type
11.4.5 Middle East & Africa Glioma Treatment Market, by Grade
11.4.5.1 Middle East & Africa Glioma Treatment Market, by Low Grade
11.4.5.2 Middle East & Africa Glioma Treatment Market, by High Grade
11.4.6 Middle East & Africa Glioma Treatment Market, by End User
11.4.7 Middle East & Africa Glioma Treatment Market, by Country
11.4.7.1 Saudi Arabia
11.4.7.1.1 Saudi Arabia Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.4.7.1.2 Saudi Arabia Glioma Treatment Market, by Disease
11.4.7.1.3 Saudi Arabia Glioma Treatment Market, by Treatment Type
11.4.7.1.4 Saudi Arabia Glioma Treatment Market, by Grade
11.4.7.1.4.1 Saudi Arabia Glioma Treatment Market, by Low Grade
11.4.7.1.4.2 Saudi Arabia Glioma Treatment Market, by High Grade
11.4.7.1.5 Saudi Arabia Glioma Treatment Market, by End User
11.4.7.2 South Africa
11.4.7.2.1 South Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.4.7.2.2 South Africa Glioma Treatment Market, by Disease
11.4.7.2.3 South Africa Glioma Treatment Market, by Treatment Type
11.4.7.2.4 South Africa Glioma Treatment Market, by Grade
11.4.7.2.4.1 South Africa Glioma Treatment Market, by Low Grade
11.4.7.2.4.2 South Africa Glioma Treatment Market, by High Grade
11.4.7.2.5 South Africa Glioma Treatment Market, by End User
11.4.7.3 UAE
11.4.7.3.1 UAE Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.4.7.3.2 UAE Glioma Treatment Market, by Disease
11.4.7.3.3 UAE Glioma Treatment Market, by Treatment Type
11.4.7.3.4 UAE Glioma Treatment Market, by Grade
11.4.7.3.4.1 UAE Glioma Treatment Market, by Low Grade
11.4.7.3.4.2 UAE Glioma Treatment Market, by High Grade
11.4.7.3.5 UAE Glioma Treatment Market, by End User
11.4.7.4 Rest of Middle East & Africa
11.4.7.4.1 Rest of Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.4.7.4.2 Rest of Middle East & Africa Glioma Treatment Market, by Disease
11.4.7.4.3 Rest of Middle East & Africa Glioma Treatment Market, by Treatment Type
11.4.7.4.4 Rest of Middle East & Africa Glioma Treatment Market, by Grade
11.4.7.4.4.1 Rest of Middle East & Africa Glioma Treatment Market, by Low Grade
11.4.7.4.4.2 Rest of Middle East & Africa Glioma Treatment Market, by High Grade
11.4.7.4.5 Rest of Middle East & Africa Glioma Treatment Market, by End User
11.5 South & Central America Glioma Treatment Market, Revenue and Forecast to 2030
11.5.1 Overview
11.5.2 South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.5.3 South & Central America Glioma Treatment Market, by Disease
11.5.4 South & Central America Glioma Treatment Market, by Treatment Type
11.5.5 South & Central America Glioma Treatment Market, by Grade
11.5.5.1 South & Central America Glioma Treatment Market, by Low Grade
11.5.5.2 South & Central America Glioma Treatment Market, by High Grade
11.5.6 South & Central America Glioma Treatment Market, by End User
11.5.6.1 South & Central America Glioma Treatment Market, by Country
11.5.6.2 Brazil
11.5.6.2.1 Brazil Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.5.6.2.2 Brazil Glioma Treatment Market, by Disease
11.5.6.2.3 Brazil Glioma Treatment Market, by Treatment Type
11.5.6.2.4 Brazil Glioma Treatment Market, by Grade
11.5.6.2.4.1 Brazil Glioma Treatment Market, by Low Grade
11.5.6.2.4.2 Brazil Glioma Treatment Market, by High Grade
11.5.6.2.5 Brazil Glioma Treatment Market, by End User
11.5.6.3 Argentina
11.5.6.3.1 Argentina Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.5.6.3.2 Argentina Glioma Treatment Market, by Disease
11.5.6.3.3 Argentina Glioma Treatment Market, by Treatment Type
11.5.6.3.4 Argentina Glioma Treatment Market, by Grade
11.5.6.3.4.1 Argentina Glioma Treatment Market, by Low Grade
11.5.6.3.4.2 Argentina Glioma Treatment Market, by High Grade
11.5.6.3.5 Argentina Glioma Treatment Market, by End User
11.5.6.4 Rest of South & Central America
11.5.6.4.1 Rest of South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
11.5.6.4.2 Rest of South & Central America Glioma Treatment Market, by Disease
11.5.6.4.3 Rest of South & Central America Glioma Treatment Market, by Treatment Type
11.5.6.4.4 Rest of South & Central America Glioma Treatment Market, by Grade
11.5.6.4.4.1 Rest of South & Central America Glioma Treatment Market, by Low Grade
11.5.6.4.4.2 Rest of South & Central America Glioma Treatment Market, by High Grade
11.5.6.4.5 Rest of South & Central America Glioma Treatment Market, by End User
12. Pre & Post Covid-19 Impact
12.1 Pre & Post Covid-19 Impact
13. Glioma Treatment Market Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 F. Hoffmann-La Roche Ltd
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Arbor Pharmaceuticals LLC
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Merck & Co Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Sun Pharmaceutical Industries Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Amgen Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Teva Pharmaceutical Industries Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Pfizer Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Amneal Pharmaceuticals Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Karyopharm Therapeutics Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Biocon Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms

ページTOPに戻る

Table of Contents

Summary

The global glioma treatment market is expected to reach US$ 8,292.5 million in 2030 from US$ 4,139.6 million in 2022. The market is projected to grow with a CAGR of 9.1% from 2022 to 2030.

The market's growth is the increasing prevalence of high-grade gliomas, including aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. However, high treatment costs hamper the market's growth to a certain extent.

Market Opportunities of Glioma Treatment Market

Brazil, India, China, Russia, and South Africa are among the fastest-growing economies in the world. The healthcare sectors in these countries and other developing economies are projected to expand rapidly in the coming years. The expected growth is due to changes in customer demand, increased awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer treatment market is likely to grow significantly in the coming years with the proliferation of the healthcare sector.

Factors Hampering Glioma Treatment Market

Treating brain tumors can be expensive, and the high cost of treatments becomes a cause of stress and anxiety for patients. In addition to the treatment cost, people need to bear additional unplanned costs related to patient care. High medical costs compel people to discontinue their treatment plans, which may put their health at risk and lead to further costs in the future. According to the National Library of Medicine, the direct medical costs of newly diagnosed, Temozolomide-treated (TMZ) GBM are substantial in commercially insured patients, with estimated total cumulative costs of ~US$ 268,031. The healthcare costs incurred by patients with malignant brain tumors are 20 times higher than those borne by non-cancer control groups with the same demographics.

Glioma Treatment Market: Segmental Overview

The glioma treatment market is segmented based on type into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest market share in 2022. Furthermore, the segment is expected to register the highest CAGR from 2022 to 2030. An upsurge in activities to raise public awareness of this condition and its treatment, coupled with the increasing prevalence of this disease, are among the major factors fueling the glioma treatment market growth. In addition, companies in the market for the anaplastic astrocytoma segment may derive growth opportunities from growing R&D efforts and new, untapped market segments. Based on treatment, the glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. In 2022, the surgery segment held the market's largest share. Also, the same segment is expected to growing demand at the fastest CAGR from 2022 to 2030, owing to the surgery being the most preferred technique as it removes the tumor completely. Based on grade, the glioma treatment market is segmented into Low Grade and High Grade. In 2022, the high-grade segment held the market's largest share. Also, the same segment is expected to growing demand at the fastest CAGR from 2022 to 2030. Multiple research studies are underway to understand better high-grade tumors to develop more effective treatments or therapies. The glioma treatment market is segmented based on end-users into hospitals & clinics, and ambulatory care centres. In 2022, the hospital & clinics segment held the largest market share. Furthermore, the same segment is expected to anticipate growth in demand at the fastest CAGR from 2022 to 2030. Further, the increasing number of hospitals, adoption of advanced diagnostic platforms, and growing accessibility of hospitals in developing nations would offer lucrative opportunities for the growth of the glioma treatment market for the hospital segment during the forecast period.

Glioma Treatment Market: Geographical Overview

North America holds the largest share of the global glioma treatment market, whereas the Asia Pacific is the fastest-growing region in the global glioma treatment market. The market in North America is expected to grow during the forecast period, primarily driven by the increasing prevalence of brain tumors, technological advancements in glioma treatment, and the rising number of smokers. Asia Pacific registered the highest CAGR in the global glioma treatment testing market. The market in the region is expected to grow significantly in countries including China, India, and Japan in the coming years. The Asia Pacific market is expected to grow due to the increasing demand for brain cancer treatments and the rising prevalence of brain tumors. Therefore, the region holds huge potential for the glioma treatment market players to grow during the forecast period.

A few of the primary and secondary sources referred to while preparing the report on the glioma treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and EPA (Environmental Protection Agency).

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（chemotherapy）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（chemotherapy）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?